Obinutuzumab for the First-Line Treatment of Follicular Lymphoma
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Obinutuzumab for the First-Line Treatment of Follicular Lymphoma have?
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma has 795 citations in the OpenAlex counts ScholarIQ stores.
When was Obinutuzumab for the First-Line Treatment of Follicular Lymphoma published?
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma has 2017 year in the ScholarIQ index.
What is the open-access status of Obinutuzumab for the First-Line Treatment of Follicular Lymphoma?
Obinutuzumab for the First-Line Treatment of Follicular Lymphoma has bronze oa status in the ScholarIQ index.
What is the DOI of Obinutuzumab for the First-Line Treatment of Follicular Lymphoma?
The DOI for Obinutuzumab for the First-Line Treatment of Follicular Lymphoma is on the source record.
What is the PMID of Obinutuzumab for the First-Line Treatment of Follicular Lymphoma?
The PMID for Obinutuzumab for the First-Line Treatment of Follicular Lymphoma is on the source record.
What is the OpenAlex record for Obinutuzumab for the First-Line Treatment of Follicular Lymphoma?
The OpenAlex for Obinutuzumab for the First-Line Treatment of Follicular Lymphoma is on the source record.